The Drug Delivery Partnerships conference focuses on collaborations to drive progress in drug delivery through uncovering new partners, new drug delivery technologies and new formulation development strategies to accelerate drugs to market and lengthen lifecycles for long-term profitability.
Dr. MacGregor's presentation will cover the following topics:
• How partnerships in delivery technology, formulation and marketing drive more products to market faster with better treatments;
• Catalent's proven ability to improve therapeutic profiles through drug delivery enhancements, i.e. ZydisÃ’ Fast-Dissolve Tablets, including innovative formulation of Grazax® as the first once-daily, oral tablet allergy immunotherapy treatment for allergy sufferers;
• Business case examples of value creation, and
• New advancements for the development of difficult to manufacture molecules with the introduction of OSDrCÃ’ OptiDoseÔ Drug Delivery Technology.
As R&D Platform Director, Dr. MacGregor brings to Catalent nearly 18 years of pharmaceutical industry experience. Prior to this role, Dr. MacGregor served as the Director of Oral Product Development (Modified Release Technologies) and European Director of Project Management for Catalent Pharma Solutions. Throughout Dr. MacGregor's career, she has held functional and leadership roles in Rhone Poulenc Rorer, Aventis, CCL Pharmaceuticals and Cardinal Health where she led technical teams in areas of formulation/process development and in operational technical support. Dr. MacGregor is a registered pharmacist in the United Kingdom, holds a doctorate from DeMontfort University in England and an MBA from the Open University.
For more information on this event, please visit here. To schedule an interview with the above mentioned presenter, during Drug Delivery Partnerships 2012 or after, please contact Patricia McGee.
To receive a copy of this presentation after the event, please visit our website.
Dr. MacGregor's presentation will cover the following topics:
• How partnerships in delivery technology, formulation and marketing drive more products to market faster with better treatments;
• Catalent's proven ability to improve therapeutic profiles through drug delivery enhancements, i.e. ZydisÃ’ Fast-Dissolve Tablets, including innovative formulation of Grazax® as the first once-daily, oral tablet allergy immunotherapy treatment for allergy sufferers;
• Business case examples of value creation, and
• New advancements for the development of difficult to manufacture molecules with the introduction of OSDrCÃ’ OptiDoseÔ Drug Delivery Technology.
As R&D Platform Director, Dr. MacGregor brings to Catalent nearly 18 years of pharmaceutical industry experience. Prior to this role, Dr. MacGregor served as the Director of Oral Product Development (Modified Release Technologies) and European Director of Project Management for Catalent Pharma Solutions. Throughout Dr. MacGregor's career, she has held functional and leadership roles in Rhone Poulenc Rorer, Aventis, CCL Pharmaceuticals and Cardinal Health where she led technical teams in areas of formulation/process development and in operational technical support. Dr. MacGregor is a registered pharmacist in the United Kingdom, holds a doctorate from DeMontfort University in England and an MBA from the Open University.
For more information on this event, please visit here. To schedule an interview with the above mentioned presenter, during Drug Delivery Partnerships 2012 or after, please contact Patricia McGee.
To receive a copy of this presentation after the event, please visit our website.
Companies in this press-release
